

## Case Report

# Ventricular Tachycardia in a Pediatric Patient with High-Risk Thrombotic Thrombocytopenia Purpura

Taylor J. Kratochvil <sup>1,2,3</sup> and Jeffrey A. Robinson <sup>4,5</sup>

<sup>1</sup>Department of Pediatrics, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA

<sup>2</sup>Department of Pediatrics, Boston Medical Center and Boston University School of Medicine, Boston, MA, USA

<sup>3</sup>College of Medicine, University of Nebraska Medical Center, Omaha, NE, USA

<sup>4</sup>Division of Cardiology, Department of Pediatrics, University of Nebraska Medical Center, Omaha, NE, USA

<sup>5</sup>The Dr. C.C. and Mabel L. Criss Heart Center, Children's Hospital and Medical Center, Omaha, NE, USA

Correspondence should be addressed to Taylor J. Kratochvil; [taylor.kratochvil@childrens.harvard.edu](mailto:taylor.kratochvil@childrens.harvard.edu) and Jeffrey A. Robinson; [jrobinson@childrensomaha.org](mailto:jrobinson@childrensomaha.org)

Received 1 September 2022; Revised 13 November 2022; Accepted 27 December 2022; Published 18 January 2023

Academic Editor: Yuli Huang

Copyright © 2023 Taylor J. Kratochvil and Jeffrey A. Robinson. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

An 8-year-old previously healthy male was diagnosed with thrombotic thrombocytopenic purpura (TTP) and increased serum cardiac troponin I. Telemetry recorded non-sustained ventricular tachycardia, without ST-segment changes or other abnormalities on serial electrocardiogram. This case illustrates that cardiac monitoring by telemetry should be considered in high-risk TTP with elevated cardiac troponin.

## 1. Introduction

Thrombotic thrombocytopenic purpura (TTP) is caused by a functional deficiency of a disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13 (ADAMTS13). ADAMTS13 is a plasma protease responsible for proteolysis of von Willebrand factor (VWF). In its absence, uncleaved VWF multimers circulate in the blood, resulting in platelet binding and increased thrombotic risk [1].

While *hereditary TTP* arises from biallelic ADAMTS13 mutations, *acquired TTP* is caused by autoantibodies increasing the rate of ADAMTS13 elimination or inhibiting its function [1]. It is estimated that only ~10% of all TTP cases occur in childhood [2], with less than one case per million children per year [3, 4], and is particularly rare in children younger than 9 years old [1].

## 2. Case Presentation

An 8-year-old Burmese male presented to the emergency department with a 7-day history of dizziness, jaundice, and

worsening ecchymoses/petechiae on the extremities and trunk. This was preceded by 2 months of fatigue and nausea, without diarrhea. Ecchymoses gradually increased in number and size, without history of trauma.

The patient was born at term in a resource-limited Thai refugee camp, and spent 1 month in the hospital for neonatal feeding support and weight gain. At 7 years of age (8 months prior to hospital presentation), the patient immigrated with his immediate family to the United States. Thrombocytopenia (platelet count:  $120 \times 10^3/\mu\text{L}$ ) and borderline anemia (hemoglobin: 11.9 g/dL) were noted at a refugee health exam, with negative screening for hepatitis B, human immunodeficiency virus, and tuberculosis. Neither the patient nor his family members have experienced similar symptoms.

The differential diagnosis for this patient included pathologies that manifest as or mimic a coagulopathy. These included severe nutritional deficiencies (e.g., iron, vitamin B12, and folate), systemic disease (e.g., hepatitis, hemolytic uremic syndrome, and disseminated intravascular coagulopathy), blood dyscrasias (e.g., leukemia, idiopathic thrombocytopenic purpura, and inherited/acquired TTP), and non-accidental trauma.

Initial values (Table 1) demonstrated thrombocytopenia, anemia, an elevated reticulocyte count, and a peripheral smear positive for schistocytes and spherocytes. Coagulation studies were normal with an elevated D-dimer. A comprehensive metabolic panel was normal for age and indicated normal kidney function. Coombs' test was negative. The patient was admitted to the hospital, where a low ADAMTS13 (<5%), and a positive inhibitor antibody confirmed the diagnosis of acquired TTP.

In consultation with the hospital's hematology team, the patient received a unit of packed red blood cells and platelets prior to the urgent placement of an internal jugular pheresis catheter for daily plasma exchange therapy (PLASMIC score of 7) [5]. In addition, the patient was started on prednisolone (0.5 mg/kg by mouth, twice daily) and rituximab (375 mg/m<sup>2</sup> intravenous, once weekly for four doses).

As TTP's microangiopathy can manifest in multiorgan damage, cardiac monitoring was initiated. The patient was found to have an elevated cardiac troponin I (peak: 0.081 ng/mL; reference range [RR]: ≤0.016 ng/mL) and intermittent ventricular tachycardia (VT)/premature ventricular contractions (Figure 1). On day 4 of admission, there was an asymptomatic 15-beat run of monomorphic VT at rest, with the shortest R-R cycle length of 330 ms.

Serum electrolytes were monitored via serial comprehensive metabolic panels, which demonstrated hypocalcemia (total serum calcium 8.6 mg/dL; ionized calcium 1.20 mmol/L). All other electrolytes were within normal limits for age. Additionally, a screening echocardiogram demonstrated normal segmental cardiac anatomy and normal biventricular size and systolic function with an anomalous origin of the right coronary artery from the left sinus of Valsalva and a small patent foramen ovale with left-to-right flow. Due to the patient's elevated cardiac troponin, prophylactic heparin was initiated and was transitioned to aspirin for oral anti-platelet therapy upon resolution of the cardiac troponinemia.

To evaluate for a potential rheumatologic etiology of the patient's symptoms, further investigation found a positive antinuclear antibody (ANA), positive anti-double stranded DNA (anti-dsDNA) antibodies, positive SSA 60, and a low C3 but normal C4. Additional lab tests demonstrated no renal (negative urinalysis and urine protein/creatinine ratio within normal limits), respiratory (pulmonary function test with spirometry, lung volumes, and diffusion capacity within normal limits), or neurovascular (unremarkable magnetic resonance imaging/magnetic resonance angiography of the brain) abnormalities. With these findings, the patient was diagnosed with systemic lupus erythematosus and was started on pulse-dosed steroids with solumedrol 30 mg/kg/day for three doses, followed by a 3-day course of high-dose, intravenous methylprednisolone 30 mg/kg/day.

Troponin levels were trended and returned to normal on day 4 of admission. Improvement in troponin levels were likely multifactorial in the setting of the patient's pharmacologic and plasma exchange treatments. Prior to hospital discharge on day 16 of admission, cardiac magnetic resonance imaging (MRI) showed no evidence of delayed gadolinium enhancement, but confirmed the anomalous origin of the

TABLE 1: Admission laboratory data.

	Lab value	Reference range
Hgb, g/dL	6.0	11.0–13.3
Platelet count, ×10 <sup>3</sup> /μL	5	150–400
ARC, ×10 <sup>6</sup> /μL	0.209	0.030–0.110
WBC, ×10 <sup>3</sup> /μL	6.59	4.5–10.5
PTT, seconds	32	24–35
PT, seconds	13.0	9.8–12.6
INR	1.1	N/A
D-dimer, ng/mL	1340	≤500

ARC = absolute reticulocyte count; Hgb = hemoglobin; INR = international normalized ratio; PT = prothrombin time; PTT = partial thromboplastin time; WBC = white blood cell count.

right coronary artery from the left sinus of Valsalva. The patient was discharged from hospital to home and prescribed aspirin, prednisolone, nizatidine, ondansetron, and acetaminophen.

The patient was scheduled for a 6-month outpatient follow-up appointment with a pediatric cardiac electrophysiologist. The patient reported no symptoms, and a Holter monitor at 6 months demonstrated sinus rhythm throughout, without evidence of ectopy or ventricular arrhythmia. Due to the patient's temporarily elevated troponin, inpatient electrophysiological derangements, and the abnormal coronary artery anatomy, he will require ongoing evaluation with a pediatric cardiologist, sequential transthoracic echocardiograms, and exercise stress testing [6]. This patient was diagnosed with systemic lupus erythematosus following the acute presentation with TTP, which is a known association in pediatric patients [7].

### 3. Discussion

Despite negative serial electrocardiograms (ECGs), this patient's asymptomatic non-sustained VT was only discovered because he was being monitored on telemetry. This illustrates the importance of monitoring cardiac troponin as a trigger for further cardiac monitoring. Adult treatment guidelines specify screening for microangiopathy and coronary artery involvement with serum cardiac troponin and ECG at the time of TTP diagnosis [8]. Though pediatric guidelines suggest cardiac troponin should be measured in patients with TTP, this may not occur due to a perceived rarity of microvascular thrombi and cardiac involvement in the children [7, 9]. In adult populations, ischemic myocardial injury has been identified postmortem as the cause of death in patients with TTP [10]. This should be considered for pediatric patients with an acute episode of acquired TTP.

Additionally, this case suggests that patients with high-risk TTP (elevated cardiac troponin) should receive cardiac monitoring by telemetry. Screening for cardiac microvascular thrombosis in patients is important, as elevated cardiac troponin is an independent risk factor for mortality in patients with TTP [11]. Monitoring for arrhythmias in patients with TTP is important, as patients who develop acute myocardial ischemia may present with atrial




FIGURE 1: Cardiac monitoring and troponin inpatient cardiac monitoring, with time measured from the patient's initial hospital presentation. PVC = premature ventricular contraction; VT = ventricular tachycardia.

fibrillation, atrial flutter, supraventricular tachycardia, or congestive heart failure [12].

It is possible that the patient's elevated troponin and electrophysiological derangements were secondary to other coexisting conditions, though the authors suspect his cardiac pathology is primarily a result of his TTP and subsequent physiologic stress on cardiac myocytes. While autoimmune rheumatologic diseases may present with electrophysiological changes, systemic lupus erythematosus is more frequently associated with sinus tachycardia, atrial fibrillation, and atrial ectopic beats [13]. Furthermore, the patient's anomalous origin of the right coronary artery from the left sinus of Valsalva was not associated with an intramural course or ostial stenosis. This is believed to be low-risk for symptoms, troponinemia, arrhythmia, and ischemia [14].

#### 4. Conclusions

This case emphasizes the importance of screening pediatric patients diagnosed with TTP for elevated cardiac troponin I. If the patient is determined to be high-risk via an elevated cardiac troponin I, subsequent telemetry monitoring during their acute illness course is important to screen for electrophysiological derangements.

#### Abbreviations

ADAMTS13: A disintegrin and metalloprotease with thrombospondin type 1 repeats, member 13  
 ECG: Electrocardiogram  
 Hgb: Hemoglobin  
 INR: International normalize ratio

PT: Prothrombin time  
 PTT: Partial thromboplastin time  
 RR: Reference range  
 TTP: Thrombotic thrombocytopenic purpura  
 VT: Ventricular tachycardia  
 WBC: White blood cell count.

#### Data Availability

The data analyzed in this study are will not be publicly released in accordance with HIPAA guidelines.

#### Conflicts of Interest

The author(s) declare(s) that they have no conflicts of interest.

#### References

- [1] A. Siddiqui, J. M. Journeycake, A. Borogovac, and J. N. George, "Recognizing and managing hereditary and acquired thrombotic thrombocytopenic purpura in infants and children," *Pediatric Blood & Cancer*, vol. 68, p. e28949, 2021.
- [2] B. S. Joly, P. Coppo, and A. Veyradier, "Thrombotic thrombocytopenic purpura," *Blood*, vol. 129, no. 21, pp. 2836–2846, 2017.
- [3] J. N. George and C. M. Nester, "Syndromes of thrombotic microangiopathy," *The New England Journal of Medicine*, vol. 371, no. 7, pp. 654–666, 2014.
- [4] B. S. Joly, A. Stepanian, T. Leblanc et al., "Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the

- French national registry for thrombotic microangiopathy,” *The Lancet Haematology*, vol. 3, no. 11, pp. e537–e546, 2016.
- [5] P. K. Bendapudi, S. Hurwitz, A. Fry et al., “Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study,” *The Lancet Haematology*, vol. 4, no. 4, pp. e157–e164, 2017.
- [6] R. Sachdeva, M. Valente Anne, A. K. Armstrong et al., “ACC/AHA/ASE/HRS/ISACHD/SCAI/SCCT/SCMR/SOPE 2020 appropriate use criteria for multimodality imaging during the follow-up care of patients with congenital heart disease,” *Journal of the American College of Cardiology*, vol. 75, no. 6, pp. 657–703, 2020.
- [7] B. S. Joly, P. Coppo, and A. Veyradier, “Pediatric thrombotic thrombocytopenic purpura,” *European Journal of Haematology*, vol. 101, no. 4, pp. 425–434, 2018.
- [8] X. L. Zheng, S. K. Vesely, S. R. Cataland et al., “Good practice statements (GPS) for the clinical care of patients with thrombotic thrombocytopenic purpura,” *Journal of Thrombosis and Haemostasis*, vol. 18, no. 10, pp. 2503–2512, 2020.
- [9] B. M. Hawkins, M. Abu-Fadel, S. K. Vesely, and J. N. George, “Clinical cardiac involvement in thrombotic thrombocytopenic purpura: a systematic review,” *Transfusion*, vol. 48, no. 2, pp. 382–392, 2008.
- [10] L. Nichols, A. Berg, M. A. Rollins-Raval, and J. S. Raval, “Cardiac injury is a common postmortem finding in thrombotic thrombocytopenic purpura patients: is empiric cardiac monitoring and protection needed?,” *Therapeutic Apheresis and Dialysis*, vol. 19, no. 1, pp. 87–92, 2015.
- [11] Y. Benhamou, P.-Y. Boelle, B. Baudin et al., “Cardiac troponin-I on diagnosis predicts early death and refractoriness in acquired thrombotic thrombocytopenic purpura. Experience of the French Thrombotic Microangiopathies Reference Center,” *Journal of Thrombosis and Haemostasis*, vol. 13, no. 2, pp. 293–302, 2015.
- [12] K. Gandhi, W. S. Aronow, H. Desai et al., “Cardiovascular manifestations in patients with thrombotic thrombocytopenic purpura: a single-center experience,” *Clinical Cardiology*, vol. 33, no. 4, pp. 213–216, 2010.
- [13] P. M. Seferović, A. D. Ristić, R. Maksimović et al., “Cardiac arrhythmias and conduction disturbances in autoimmune rheumatic diseases,” *Rheumatology*, vol. 45, suppl 4, pp. iv39–iv42, 2006.
- [14] M. K. Cheezum, R. R. Liberthson, N. R. Shah et al., “Anomalous aortic origin of a coronary artery from the inappropriate sinus of Valsalva,” *Journal of the American College of Cardiology*, vol. 69, no. 12, pp. 1592–1608, 2017.